ArticleAnti-cancer agents in medicinal chemistry2026
Thiourea Derivatives for the Potential Treatment of Lung Cancer via the Inhibition of EGFR and Efflux Pumps: Synthesis,
Article in Anti-cancer agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe overexpression and/or mutations of Epidermal Growth Factor Receptor (EGFR) are associated with the progression of several cancers. Thiourea derivatives have emerged as promising compounds to target EGFR for cancer treatment.
methodsTen thiourea derivatives (1-10) underwent virtual screening, were synthesized, and evaluated on EGFR-expressing cells and normal fibroblasts. RESULTS AND DISCUSSION: Compound 3 had the highest binding affinity towards HER1 and HER2 (EGFR family) with the Lowest Binding Energy (LBE) values of -9.6 and -10.9 kcal/mol, respectively. Against lung cancer cells, H69 and H2073 cells, compound 3 had IC
conclusionCompound 3 has shown to have cytotoxic effects against EGFR-expressing lung cancer cells, causes an additive effect with conventional chemotherapy, and may be used to treat multi-drug-resistant cancers.
Indexed as
Identifiers
41833022What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.